Streetbeat News

Stock Prices

INTC

Intel Corporation's stock has been trending higher despite recent threats from China to semiconductor and tech stocks. The stock gained last week even as the sector weakened due to China's plans to restrict iPhone usage and Huawei's announcement of a new smartphone. Intel's presentation at the Citi Global Technology Conference was viewed positively by Citi analyst Christopher Danely.

Portfolio Pulse from Ryan Gustafson

September 11, 2023 | 8:20 pm

SGHT

Sight Sciences has issued Q3 total revenue guidance below estimates and also cut its FY23 revenue guidance below estimates. This has led to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 8:18 pm

ABUS

Arbutus Biopharma Corporation has announced that it will discontinue all its coronavirus and oral RNA destabilizer programs, including AB-343 and AB-161. The company expects these pipeline changes to extend its cash runway through Q3 2025.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 8:17 pm

LRCX

A significant bearish stance has been taken on Lam Research (NASDAQ:LRCX) as indicated by unusual options activity. The overall sentiment of these big-money traders is split between 19% bullish and 80% bearish. Whales have been targeting a price range from $450.0 to $750.0 for Lam Research over the last 3 months. Stifel has maintained their Buy rating on Lam Research, with a price target of $750.

Portfolio Pulse from Benzinga Insights

September 11, 2023 | 8:16 pm

ORCL

Oracle reported mixed Q1 financial results, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 8:14 pm

CLDI

First Light Acquisition Group has announced that its business combination transaction with Calidi Biotherapeutics has been approved for listing on the NYSE. The transaction, expected to be completed on September 12, 2023, will provide Calidi with approximately $28 million in gross proceeds. Additionally, Calidi has secured a forward purchase agreement for up to $10 million with a consortium including Meteora Capital LLC, Great Point Capital LLC, and Funicular Funds, LP. The listed company will be named Calidi Biotherapeutics, Inc. and will trade under the ticker symbols 'CLDI' and 'CLDI WS'.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 8:13 pm

SLRN

Trading of ACELYRIN, INC. common stock shares is set to resume at 4:35 p.m. ET.

Portfolio Pulse from Bill Haddad

September 11, 2023 | 8:12 pm

SGHT

Sight Sciences has reduced its FY23 revenue guidance from $89M-$94M to $80M-$82M, which is significantly lower than the estimated $92.12M.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 8:12 pm

ARKK

PP

TSLA

Tesla's stock soared by over 10% on Monday, increasing the company's market cap by $80 billion. The surge was driven by Morgan Stanley's analyst Adam Jonas upgrading Tesla's stock from Equalweight to Overweight and hiking the price target from $250 to $400. The optimism is rooted in the potential of Tesla's Dojo supercomputer, which could add $500 billion to Tesla's enterprise value. ETFs with significant Tesla exposure also saw gains, with The Meet Kevin Pricing Power ETF (NYSE:PP) leading the pack with a 3.2% surge.

Portfolio Pulse from Piero Cingari

September 11, 2023 | 8:11 pm

AVO

Mission Produce expects Q4 industry volumes to be flat or slightly lower year-over-year. However, pricing is expected to be flat or slightly higher on a year-over-year basis by approximately 10%.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 8:10 pm